I'm LongbridgeAI, I can summarize articles.CQP announced that its controlling subsidiary Chongqing Pharmaceutical (Group) Co., Ltd. has received the "Acceptance Notice" from the National Medical Products Administration for the drug Clopidogrel Hydrochloride Tablets. This drug is a third-generation ADP-activated platelet aggregation inhibitor, suitable for the prevention of thrombosis in patients with acute coronary syndrome, stable angina, and old myocardial infarction
According to the Zhitong Finance APP, Chongqing Pharmaceutical (Group) Co., Ltd. (referred to as "Chongyao Shares"), a controlling subsidiary of Chongqing Pharmaceutical Holdings (000950.SZ), has received the "Acceptance Notification" issued by the National Medical Products Administration, for the drug named: Clopidogrel Hydrochloride Tablets.
The announcement shows that the original research company for Clopidogrel Hydrochloride Tablets is Daiichi Sankyo Company, Limited, which is a third-generation drug that inhibits ADP-induced platelet aggregation, suitable for the prevention of acute coronary syndrome after percutaneous coronary intervention, stable angina, and thrombosis in patients with old myocardial infarction